Rituximab in Myasthenia Gravis- Experience from a Low- and Middle-Income Country (LMIC) Setting.

Sumanth Shivaram,Madhu Nagappa,Nibu Varghese,Doniparthi V Seshagiri, Shishir Duble, Shreedhara Anjanapura Siddappa,Nagabushan Hesarur,Sanjib Sinha,Arun B Taly

Neurology India（2022）

引用 0|浏览8

暂无评分

摘要

Rituximab was effective in bringing about remission in MG and can be considered as a first-line agent. However, it has to be administered under close supervision as some patients develop exacerbation of MG akin to steroid-induced worsening.

查看译文

关键词

MG-PIS,MG-STI,myasthenia gravis,rituximab,rituximab induced exacerbation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要